Marker Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $1,926 | $1,169 | $1,244 | $1,056 |
Gross Profit | 1,926 | 1,169 | -1,330 | -1,560 |
EBITDA | -2,399 | -2,308 | -2,549 | -2,937 |
EBIT | -5,098 | -3,635 | ||
Net Income | -2,308 | -2,192 | -2,392 | -2,740 |
Net Change In Cash | 1,926 | 1,169 | 1,244 | 1,056 |
Free Cash Flow | 1,197 | -3,567 | -3,837 | -2,367 |
Cash | 8,999 | 7,800 | 11,323 | 15,111 |
Basic Shares | 8,923 | 8,918 | 8,901 | 8,900 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $3,311 | $9,004 | $1,241 | $466 |
Gross Profit | -7,105 | 5,324 | -1,920 | -18,413 |
EBITDA | -11,792 | -19,791 | -36,315 | -27,630 |
EBIT | -14,581 | -23,471 | -39,477 | -28,706 |
Net Income | -14,045 | -29,915 | -41,873 | -28,526 |
Net Change In Cash | 3,311 | 9,004 | 1,241 | 466 |
Cost of Revenue | -22,551 | |||
Free Cash Flow | -16,439 | -31,917 | -30,410 | -29,287 |
Cash | 15,111 | 11,782 | 42,351 | 21,352 |
Basic Shares | 8,809 | 8,351 | 7,650 | 4,703 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.26 |
2024-06-30 | -$0.29 |
2024-03-31 | -$0.27 |
2023-12-31 | -$0.48 |
